Login Register Cart 0
Research Article

高表达IL-6基因多态性在中国人乳头状甲状腺癌易感性中的作用

卷 19, 期 6, 2019

页: [443 - 451] 页: 9

弟呕挨: 10.2174/1566524019666190426142432

价格: $65

摘要

背景：甲状腺乳头状癌（PTC）是甲状腺癌的主要组织学类型，是最常见的内分泌恶性肿瘤。基于癌症基因组图谱（TCGA）和基因组 - 组织表达（GTEx）数据库，在甲状腺癌（THCA）样品中发现IL-6的表达高于配对的正常组织。在这项研究中，我们旨在调查白细胞介素-6（IL-6）多态性与PTC风险之间的关联。 方法：使用以下数据设计病例对照研究：241名PTC患者和463名健康对照。选择IL-6中的5个单核苷酸多态性（SNP）并使用Agena MassARRAY技术进行基因分型。 结果：我们的结果显示，SNP rs1800796与共显性模型（p = 0.042）和显性模型（p = 0.027）中PTC风险增加有关。 Rs1524107也是共显性模型（p = 0.003），显性模型（p = 0.002）和对数加性模型（p = 0.044）中PTC易感性的风险因素。此外，rs2066992显着增加了共显性模型和显性模型中的PTC风险（分别为p = 0.011，p = 0.009）。此外，rs2069837变体基于显性模型提高了PTC风险（p = 0.041）。在计算机分析中，已知rs1800796，rs1524107和rs2066992变体的GTEx结果与IL-6基因表达相关。使用HaploReg，我们发现LD中的rs1800796，rs1524107和rs2066992具有功能重要性。 结论：我们的研究表明，IL-6变异可能是PTC发病机制和发展过程中的一个风险因素。

关键词: 甲状腺乳头状癌（PTC），白细胞介素-6（IL-6），单核苷酸多态性（SNP），功能注释，MassARRAY技术，GTEx。

« Previous Next »
[1]
Lubitz CC, Sosa JA. The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients. Cancer 2016; 122: 3754-9.
[2]
Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 2017; 317: 1338-48.
[3]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[4]
La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer 2015; 136: 2187-95.
[5]
He W, Qi B, Zhou Q, et al. Key genes and pathways in thyroid cancer based on gene set enrichment analysis. Oncol Rep 2013; 30: 1391-7.
[6]
Gudmundsson J, Thorleifsson G, Sigurdsson JK, et al. A genome-wide association study yields five novel thyroid cancer risk loci. Nat Commun 2017; 8: 14517-24.
[7]
Son HY, Hwangbo Y, Yoo SK, et al. Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer. Nat Commun 2017; 8: 15966-77.
[8]
Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015; 125: 3347-55.
[9]
Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014; 15: e493-503.
[10]
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6: a016295.
[11]
Tindall EA, Severi G, Hoang HN, et al. Interleukin-6 promoter variants, prostate cancer risk, and survival. Prostate 2012; 72: 1701-7.
[12]
Yu J, Jia Y, Cheung KF, et al. Polymorphisms in interleukin-6-6331 influences the susceptibility of a Chinese population to gastric cancer. Cancer Invest 2011; 29: 564-72.
[13]
Shi TY, Zhu ML, He J, et al. Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women. Hum Genet 2013; 132: 301-12.
[14]
Sghaier I, Mouelhi L, Rabia NA, et al. Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma in HCV infected patients. Cytokine 2017; 89: 62-7.
[15]
Zhao XM, Gao YF, Zhou Q, Pan FM, Li X. Relationship between interleukin-6 polymorphism and susceptibility to chronic hepatitis B virus infection. World J Gastroenterol 2013; 19: 6888-93.
[16]
Li Z, Zhang Z, He Z, et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res 2009; 19: 519-23.
[17]
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
[18]
Consortium. G. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science 2015; 348: 648-60.
[19]
Ward LD, Kellis M. HaploReg v4: Systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res 2016; 44: D877-81.
[20]
Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149-57.
[21]
Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014; 26: 54-74.
[22]
Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 2011; 3: 177-89.
[23]
Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: A villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int 2014; 13: 371-80.
[24]
Ataie-Kachoie P, Pourgholami MH, Morris DL. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev 2013; 24: 163-73.
[25]
Ho LJ, Luo SF, Lai JH. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers. Biochem Pharmacol 2015; 97: 16-26.
[26]
Provatopoulou X, Georgiadou D, Sergentanis TN, et al. Interleukins as markers of inflammation in malignant and benign thyroid disease. Inflamm Res 2014; 63: 667-74.
[27]
Ruggeri RM, Villari D, Simone A, et al. Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor. J Endocrinol Invest 2002; 25: 959-66.
[28]
Kobawala TP, Trivedi TI, Gajjar KK, Patel DH, Patel GH, Ghosh NR. Significance of Interleukin-6 in Papillary Thyroid Carcinoma. J Thyroid Res 2016; 2016: 6178921.
[29]
Tang S, Yuan Y, He Y, et al. Genetic polymorphism of interleukin-6 influences susceptibility to HBV-related hepatocellular carcinoma in a male Chinese Han population. Hum Immunol 2014; 75: 297-301.
[30]
Huang WJ, Wu LJ, Min ZC, et al. Interleukin-6 -572G/C polymorphism and prostate cancer susceptibility. Genet Mol Res 2016; 15: 1-9.
[31]
Wang W, Chen J, Zhao F, Zhang B, Yu H. Lack of association between a functional polymorphism (rs1800796) in the interleukin-6 gene promoter and lung cancer. Diagn Pathol 2014; 9: 134.
[32]
Yin YW, Sun QQ, Hu AM, et al. Associations between interleukin-6 gene -174 C/G and -572 C/G polymorphisms and the risk of gastric cancer: a meta-analysis. J Surg Oncol 2012; 106: 987-93.
[33]
Ma Y, Tang RK, Yang X, et al. Lack of an association between interleukin-6 gene promoter polymorphisms
(-174G/C, -572G/C) and ischemic heart disease and/or ischemic stroke: A meta-analysis. Hum Immunol 2011; 72: 641-51.
[34]
Cenit MC, Simeon CP, Vonk MC, et al. Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol 2012; 39: 2294-302.
[35]
Farhat SB, de Souza CM, Braosi AP, et al. Complete physical mapping of IL6 reveals a new marker associated with chronic periodontitis. J Periodontal Res 2017; 52: 255-61.
[36]
Inoue N, Watanabe M, Morita M, et al. Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases. Clin Exp Immunol 2011; 163: 318-23.

Rights & Permissions Print Cite
Article Metrics
38
3
1
© 2024 Bentham Science Publishers | Privacy Policy